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In the original publication of the article, the ) for SU6656, anti-CXCR5-antibody, PI-103-treated ROE ? LT cells normalized with internal control and quantified. Fold changes in MDA-MB-231 were as follows: Vimentin decreased 4.4, 3.7, 4.0-fold, respectively; N-cadh decreased 22.5, 31.8, 36.3-fold, respectively; Snail decreased 16.1, 17.2, 16.7-fold, respectively; Slug decreased 2.2, 8.33, 3.9-fold, respectively; and MMP9 decreased 7.7, 12.5, 20.0-fold, respectively. For T-47D cells, fold changes were as follows: Vimentin decreased 24.9, 37.3, 38.5-fold, respectively; N-cadh decreased 17.3, 38.6, 34.2-fold, respectively; Snail decreased 26.0, 38.5, 35.1-fold, respectively; Slug decreased 3.1, 5.7, 8.2-fold, respectively; and MMP9 was decreased 5.9, 37.3, 16.5-fold, respectively. E-cadh expression increased significantly in all the treatment conditions for T-47D cells. RANKL expression, however, decreased significantly only upon anti-CXCR5 treatment. No treatment had any effect on CXCR5 mRNA level. c Expressions of Vimentin, Slug, Snail, N-cadh, E-cadh, RANKL, and CXCR5 were evaluated by immunoblotting. b-actin was used as loading control. Vimentin, Slug, Snail, and N-cadh expressions were decreased in SU6656, PI-103, anti-CXCR5-antibody treated ROE ? LT cells. Inhibitor/anti-CXCR5-antibody treated ROE ? LT T-47D cells have decreased E-cadh expression. RANKL expression was only found to be downregulated in anti-CXCR5-antibody treated ROE ? LT cells. d WB band densitometries shown in bar graphs. Results are representative of three independent experiments performed in triplicate and are represented as mean ± SD. One-way ANOVA (Bonferroni correction) was performed, where significance level stands for *p B 0.05, **p B 0.01, ***p B 0.001
